Proposed pathway for systematic MASLD/MASH assessment in type 2 diabetesNew Pathway Proposed to Manage Liver Disease in Diabetes Patients
Frontiers in MedicinePublished July 30, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider this proposed pathway for MASLD/MASH assessment in T2DM as a conceptual framework, not a validated protocol.
This narrative review proposes a structured, risk-adapted outpatient pathway for the assessment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) in patients with type 2 diabetes mellitus (T2DM). The pathway begins with automated FIB-4 calculation, followed by second-line non-invasive assessment using FibroScan or enhanced liver fibrosis testing for indeterminate or high-risk results. The goal is to transition from incidental recognition to systematic, multidisciplinary risk management in endocrinology outpatient clinics.
The review does not provide clinical trial data for the efficacy of this specific pathway; it is a theoretical framework based on existing non-invasive testing modalities. The authors do not report effect sizes, p-values, or confidence intervals, as no primary outcomes were measured. The proposed pathway is intended to facilitate risk stratification and structured management, but its real-world effectiveness remains unvalidated.
Limitations include the narrative review format and the lack of clinical trial evidence supporting the pathway. The authors acknowledge that this is a proposed pathway rather than a tested intervention. Practice relevance is limited to conceptual guidance; clinicians should await prospective validation before implementing the pathway in routine care.
How this fits prior evidence
This narrative review addresses a gap in prior coverage by proposing a systematic assessment pathway for MASLD/MASH in T2DM, complementing earlier reviews on metabolic surgery and incretin-based therapies. It extends the focus from cardiovascular and glycemic outcomes to liver disease, which was not covered in prior items on SGLT2 inhibitors, GLP-1 receptor agonists, or vitamin D deficiency.
The proposed plan starts with an automated FIB-4 calculation. If the results are unclear or show high risk, doctors would then use second-line tests like FibroScan or enhanced liver fibrosis testing. This approach is designed to help healthcare teams better categorize and manage risks in a clinic setting.
It is important to note that this was a narrative review of a proposed pathway rather than a clinical trial. Because there is no trial data, the effectiveness of this specific method has not been tested in a large group of patients. Readers should view this as a theoretical framework for doctors to consider when organizing care.
What this means for you:
A new suggested system aims to help doctors better identify liver issues in patients with type 2 diabetes.
Common questions
What is the purpose of this new assessment pathway?
The goal of the proposed pathway is to move from incidental recognition of liver issues to a systematic, multidisciplinary risk management system. It aims to help doctors with patients who have type 2 diabetes better identify and assess conditions like MASLD and MASH using specific tools like FIB-4 calculations and FibroScan testing.
How does the proposed screening process work?
The suggested pathway begins with an automated FIB-4 calculation. If that result is indeterminate or shows a high risk, the plan suggests moving to second-line non-invasive assessments. These include FibroScan or enhanced liver fibrosis testing to provide a clearer picture of the patient's liver health.
Is this new method proven to work for patients?
This was a narrative review of a proposed pathway, not a clinical trial. This means there is no specific data on how well this system works in practice yet. It is currently a theoretical framework for doctors rather than an established, tested treatment or diagnostic standard.
Patients with type 2 diabetes mellitus (T2DM) have a high burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), but liver fibrosis risk is still not assessed consistently in routine diabetes care. Recent guidelines now support active fibrosis risk stratification in metabolically high-risk populations, yet many endocrinology clinics lack a workable pathway for implementation. This narrative review proposes a risk-adapted outpatient pathway for MASLD/MASH assessment in patients with T2DM. The pathway starts with automated fibrosis-4 index (FIB-4) calculation using routine laboratory data, followed by second-line non-invasive assessment with FibroScan controlled attenuation parameter/liver stiffness measurement or enhanced liver fibrosis testing in patients with indeterminate or high-risk results. Patients at high risk should be referred for hepatology evaluation, with magnetic resonance imaging-proton density fat fraction or magnetic resonance elastography reserved for selected cases in which quantitative assessment or further staging would alter management. The review also addresses implementation barriers, appropriate use of non-invasive tests, treatment strategies with metabolic and liver-related evidence, and validation indicators for real-world assessment. By linking screening, referral, intervention, follow-up and quality control, the proposed pathway aims to move MASLD/MASH care in T2DM from incidental recognition toward structured, measurable and multidisciplinary risk management.
